论文部分内容阅读
TNP-470是半合成的烟曲霉素类似物,具有较强的抗血管生成活性.为了验证其抗癌作用,本文将Walker256肉瘤细胞接种于Wistar大鼠皮下(2×10~7/鼠),将50只大鼠随机分成A、B、C、D E5组.第二天起分别给予生理盐水.TNP-470(30、50、100mg/kg)、CTX(30mg/kg)S.C.,q.o.d.第九天时,A、B、C、D、E各组皮下瘤重分别为3.88±1.24、2.20±0.58、1.64±0.25、0.86±0.30、1.17±0.33克.经统计学检验表明TNP-470能明显抑制Walker256肉瘤的生长,而且其抑制作用具有剂量相关性.对皮下肿瘤的病理研究发现:给TNP-470各组的肿瘤血管数目明显少于其他两组,而肿瘤坏死程度显著高于其他两组.该结果支持TNP-470通过抑制血管生成而抑制肿瘤生长
TNP-470 is a semi-synthetic fumagillin analog with strong anti-angiogenic activity. In order to verify its anti-cancer effect, Walker256 sarcoma cells were inoculated subcutaneously into Wistar rats (2×10~7/rat). 50 rats were randomly divided into groups A, B, C, and D E5. Normal saline, TNP-470 (30, 50, and 100 mg/kg), and CTX (30 mg/kg) SC were given on the second day. At nine days, the subcutaneous tumor weights in groups A, B, C, D, and E were 3.88±1.24, 2.20±0.58, 1.64±0.25, 0.86±0.30, and 1.17±0.33 g, respectively. Statistical tests showed that TNP-470 could Obviously inhibited the growth of Walker256 sarcoma, and its inhibitory effect was dose-related. The pathological study of subcutaneous tumors found that the number of tumor vessels given to each group of TNP-470 was significantly less than the other two groups, and the degree of tumor necrosis was significantly higher than the other two Group. This result supports TNP-470 inhibiting tumor growth by inhibiting angiogenesis